Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fluoroquinolone Clear all
Completed No phase listed Observational

Risk of Acute Liver Injury in Users of Antimicrobials

NCT01434173
View directory record Official record
Conditions
Drug-Induced Liver Injury
Interventions
Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,299,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Many Locations, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli

NCT00376376
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levofloxacin at 250, 500, 750, and 1000 mg doses
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

NCT03479736
View directory record Official record
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

NCT00473460
View directory record Official record
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

NCT00003824
View directory record Official record
Conditions
Bladder Cancer
Interventions
cephalexin, surgical procedure, Ciprofloxacin
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
90
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

FQ Restriction for the Prevention of CDI

NCT03848689
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions
fluoroquinolone preprescription authorization, Control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
5,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics

NCT02223338
View directory record Official record
Conditions
Bacterial Resistance
Interventions
Ciprofloxacin, Standard Aseptic Technique
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362
View directory record Official record
Conditions
Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

BK Treatment Study

NCT01034176
View directory record Official record
Conditions
BK Viremia
Interventions
levofloxacin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Ciprofloxacin for Prevention of BK Infection

NCT01789203
View directory record Official record
Conditions
BK Virus Infection
Interventions
Ciprofloxacin, placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated No phase listed Observational Results available

Fluoroquinolone Resistance Prevalence Study

NCT05824689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Study of Ocular Penetration of Topically Administered Fluoroquinolones

NCT00924729
View directory record Official record
Conditions
Cataract Extraction
Interventions
Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Fluoroquinolone Associated Disability

NCT03535558
View directory record Official record
Conditions
Bronchitis, Sinusitis, Urinary Tract Infections
Interventions
Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
239,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

NCT04710212
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
Interventions
No intervention.
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
San Francisco, California • Nutley, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

NCT00915213
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Irvine, California • Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

NCT00392275
View directory record Official record
Conditions
Cataract
Interventions
Ofloxacin 0.3%, Ciprofloxacin 0.3%, Levofloxacin 0.5%, Ofloxacin 400mg, Ciprofloxacin 400mg, Levofloxacin 250mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

NCT03850509
View directory record Official record
Conditions
Crohn's Disease
Interventions
OPS-2071, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
24
States / cities
Los Angeles, California • San Carlos, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

NCT00719810
View directory record Official record
Conditions
Skin Structure Infections, Bacterial Skin Diseases, Staphylococcal Skin Infections
Interventions
delafloxacin, tigecycline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Anaheim, California • Hawaiian Gardens, California • Oceanside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00414011
View directory record Official record
Conditions
Epithelium, Corneal
Interventions
Moxifloxacin, Gatifloxacin
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational Results available

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

NCT00210639
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
No intervention
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
6 Months to 16 Years
Enrollment
2,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
47
States / cities
Hoover, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 11:02 AM EDT